Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7843173> ?p ?o }
Showing triples 1 to 40 of
40
with 100 triples per page.
- Q7843173 subject Q7139608.
- Q7843173 subject Q7311092.
- Q7843173 subject Q8728165.
- Q7843173 subject Q8808791.
- Q7843173 subject Q8965786.
- Q7843173 abstract "Trioxifene (LY-133,314) was a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor-alpha (ERα) and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer, but was abandoned.".
- Q7843173 atcPrefix "none".
- Q7843173 casNumber "63619-84-1".
- Q7843173 fdaUniiCode "R0130F043H".
- Q7843173 iupacName "[2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone".
- Q7843173 pubchem "50139".
- Q7843173 thumbnail Trioxifene.png?width=300.
- Q7843173 wikiPageWikiLink Q128581.
- Q7843173 wikiPageWikiLink Q181257.
- Q7843173 wikiPageWikiLink Q26972.
- Q7843173 wikiPageWikiLink Q410943.
- Q7843173 wikiPageWikiLink Q416496.
- Q7843173 wikiPageWikiLink Q422416.
- Q7843173 wikiPageWikiLink Q632240.
- Q7843173 wikiPageWikiLink Q6507061.
- Q7843173 wikiPageWikiLink Q7139608.
- Q7843173 wikiPageWikiLink Q7311092.
- Q7843173 wikiPageWikiLink Q8728165.
- Q7843173 wikiPageWikiLink Q8808791.
- Q7843173 wikiPageWikiLink Q8965786.
- Q7843173 wikiPageWikiLink Q903917.
- Q7843173 wikiPageWikiLink Q912894.
- Q7843173 atcPrefix "none".
- Q7843173 casNumber "63619".
- Q7843173 iupacName "[2--3,4-dihydronaphthalen-1-yl]-[4-phenyl]methanone".
- Q7843173 pubchem "50139".
- Q7843173 unii "R0130F043H".
- Q7843173 type ChemicalSubstance.
- Q7843173 type Drug.
- Q7843173 type ChemicalObject.
- Q7843173 type Thing.
- Q7843173 type Q8386.
- Q7843173 comment "Trioxifene (LY-133,314) was a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor-alpha (ERα) and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer, but was abandoned.".
- Q7843173 label "Trioxifene".
- Q7843173 depiction Trioxifene.png.